Thursday, June 11, 2026

Intelligence Β· INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Showing page 139 of 200 Β· By data quality, then INN

  1. tisotumab vedotin

    TIVDAK

    EMA: approved

    L01FX23
  2. tivozanib hydrochloride monohydrate

    FOTIVDA

    EMA: approved

    L01EK03
  3. tixagevimab

    EVUSHELD

    EMA: withdrawn

  4. tocofersolan

    VEDROP

    EMA: approved

    A11HA08
  5. tolebrutinib

    CENRIFKI

    EMA: unknown

  6. toremifene

    FARESTON Orion Laboratories Pty.

    EMA: approved Β· TGA: approved

    L02BA02
  7. toripalimab

    ZYTORVI Dr Reddy''s Laboratories (Australia) Pty Ltd

    EMA: approved Β· TGA: approved Β· NMPA: clinical trials

    L01FF13
  8. trastuzumab deruxtecan

    ENHERTU AstraZeneca

    EMA: approved Β· TGA: approved Β· PMDA: approved

    L01FD04
  9. trastuzumab duocarmazine

    JIVADCO

    EMA: application withdrawn

  10. trastuzumab emtansine

    KADCYLA Hoffmann-La Roche

    EMA: approved Β· TGA: approved Β· PMDA: approved

    L01FD03
  11. tremelimumab

    IMJUDO AstraZeneca

    EMA: approved Β· TGA: approved

    L01FX20
  12. trenonacog alfa

    IXINITY

    EMA: application withdrawn

    B02BD12
  13. trientine

    TRIENTINE DR. REDDY''S Dr Reddy''s Laboratories (Australia) Pty Ltd

    EMA: approved Β· TGA: approved

    A16AX
  14. trientine dihydrochloride

    CUFENCE

    EMA: approved

    A16A
  15. trivalent influenza vaccine (recombinant, prepared in cell culture)

    SUPEMTEK

    EMA: approved

    J07BB02
  16. troriluzole

    DAZLUMA

    EMA: application withdrawn

    N07XX
  17. trovafloxacin

    TURVEL

    EMA: withdrawn

    J01MA13
  18. turoctocog alfa

    NOVOEIGHT

    EMA: approved Β· PMDA: approved

    B02BD02
  19. turoctocog alfa pegol

    ESPEROCT

    EMA: approved

    B02BD02
  20. ublituximab

    BRIUMVI NEURAXPHARM AUSTRALIA PTY LIMITED

    EMA: approved Β· TGA: approved

    L04
  21. ulipristal

    ESMYA

    EMA: withdrawn

    G03XB02
  22. umeclidinium

    INCRUSE ELLIPTA GlaxoSmithKline

    EMA: approved Β· TGA: approved

    R03BB07
  23. vardenafil

    LEVITRA

    EMA: approved

    G04BE09
  24. velmanase alfa

    LAMZEDE

    EMA: approved

    A16AB15

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles β€” INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page β€” it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.